---
reference_id: "PMID:33264544"
title: Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
authors:
- André T
- Shiu KK
- Kim TW
- Jensen BV
- Jensen LH
- Punt C
- Smith D
- Garcia-Carbonero R
- Benavides M
- Gibbs P
- de la Fouchardiere C
- Rivera F
- Elez E
- Bendell J
- Le DT
- Yoshino T
- Van Cutsem E
- Yang P
- Farooqui MZH
- Marinello P
- Diaz LA Jr
- KEYNOTE-177 Investigators
journal: N Engl J Med
year: '2020'
doi: 10.1056/NEJMoa2017699
content_type: abstract_only
---

# Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
**Authors:** André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr, KEYNOTE-177 Investigators
**Journal:** N Engl J Med (2020)
**DOI:** [10.1056/NEJMoa2017699](https://doi.org/10.1056/NEJMoa2017699)

## Content

1. N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

André T(1), Shiu KK(1), Kim TW(1), Jensen BV(1), Jensen LH(1), Punt C(1), Smith 
D(1), Garcia-Carbonero R(1), Benavides M(1), Gibbs P(1), de la Fouchardiere 
C(1), Rivera F(1), Elez E(1), Bendell J(1), Le DT(1), Yoshino T(1), Van Cutsem 
E(1), Yang P(1), Farooqui MZH(1), Marinello P(1), Diaz LA Jr(1); KEYNOTE-177 
Investigators.

Collaborators: Atkinson V, Price T, Gibbs P, Horvath L, Pavlakis N, Strickland 
A, Tsoi D, Van Cutsem E, Van den Eynde M, Van Laethem JL, Bragagnoli AC, 
Bragagnoli MI, Alves G, Girotto G, Burkes R, Kavan P, Sawyer M, Lemay F, 
Pfeiffer P, Jensen LH, Jensen B, Lamminmaki A, Halonen P, Salminen T, Ristamaki 
R, Hiret S, Smith D, Taieb J, Raimbourg J, Turpin A, Ychou M, de la 
Fourchardiere C, Seitz JF, Malka D, Andre T, Guimbaud R, Heinemann V, Jaeger D, 
Moehler M, Al-Batran SE, Karthaus M, Striefler J, Gallagher D, McDermott R, Geva 
R, Shacham-Schmueli E, Stemmer S, Ciardiello F, Esaki T, Nishina T, Ebi H, 
Yoshino T, Denda T, Moriwaki T, Komatsu Y, Yamakazi K, Hamamoto Y, Hara H, 
Kawakami H, Takashima A, Masuishi T, Yoshida K, Satoh T, Yamaguchi K, Yamaguchi 
T, Oki E, Kato T, Punt C, De Groot D, Koopman M, de Groot J, Braendengen M, 
Hamre H, Hofsli E, Koo SL, Kong WP, Chan SW, Szpak W, Coetzee C, Shepherd L, 
Kraus P, Naicker P, Landers G, Kim TY, Kim TW, Park YS, Ahn JB, Rivera F, Garcia 
Carbonero R, Sastre Valera J, Tabernero J, Manzano Mozo J, Cervantes Ruizpere A, 
Benavides M, Rodriguez M, Ullenhag G, Carlsson G, Eberhard J, Siebenhuener A, 
Weisshaupt C, Keeberle D, Fernandez E, Chen HH, Yeh KH, Yang TS, Wang HM, Yeh 
YM, Teng HW, Arkenau HT, Samuel L, Shiu KK, Coyle V, Goranov B, Baijal S, Acoba 
J, Acoba JD, Anderson I, Beg M, Bendell J, Berg D, Draper D, Fountzilas C, Le D, 
George TJ, Gold PJ, Noonan A, Hall M, Wollner I, Krishnamurthy A, Lenz HJ, Morse 
M, Poplin E, Rajdev L, Polite B, Rojan A, Siegel R, Vaccaro G, Wainberg Z, Mayer 
RJ, Marshall J, Hubbard JM, Fisher GA, Musher BL, Kortmansky J, Zell J, Liew C, 
McNamara M, Rocha Lima C, Cultrera JL, Reeves JA, Philip PA, Bleeker J, 
Ramanathan R, Nallapareddy S, Fleischauer SK, Huyck TK, Paulson AS, Richards DA, 
Shao SH, Lammers P, McCune SL, Zalupski M, Cline-Burkhardt VJM, Schlechter B, 
Blaszkowsky L, Finley G, Suga JM, Buchschacher G, Toomey K, Kassem M, Hantel A, 
Treisman JS, Lin A, Diaz L, Madani A, Suga JM, Treisman J, Lal I, Kio E, Chu D, 
DiSean Kendall S, Kozloff M.

Author information:
(1)From Sorbonne Université and Hôpital Saint Antoine, Paris (T.A.), Bordeaux 
University Hospital, Bordeaux (D.S.), and Léon Bérard Center, Lyon (C.F.) - all 
in France; University College Hospital, NHS Foundation Trust, London (K.-K.S.); 
Asan Medical Center, University of Ulsan, Seoul, South Korea (T.W.K.); Herlev 
and Gentofte Hospital, Herlev (B.V.J.), and University Hospital of Southern 
Denmark, Vejle (L.H.J.) - both in Denmark; Amsterdam University Medical Center, 
University of Amsterdam, Amsterdam (C.P.); Hospital Universitario 12 de Octubre, 
Imas12, Madrid (R.G.-C.), Hospital Regional Universitario, Malaga (M.B.), 
Hospital Universitario Marques de Valdecilla, Santander (F.R.), and Vall 
d'Hebron Institute of Oncology, Barcelona (E.E.) - all in Spain; Western Health, 
St. Albans, VIC, Australia (P.G.); Sarah Cannon Research Institute-Tennessee 
Oncology, Nashville (J.B.); Sidney Kimmel Comprehensive Cancer Center at Johns 
Hopkins, Baltimore (D.T.L.); National Cancer Center Hospital East, Kashiwa, 
Japan (T.Y.); University Hospital Gasthuisberg and KU Leuven, Leuven, Belgium 
(E.V.C.); MSD China, Beijing (P.Y.); Merck, Kenilworth, NJ (M.Z.H.F., P.M.); and 
Memorial Sloan Kettering Cancer Center, New York (L.A.D.).

Comment in
    N Engl J Med. 2020 Dec 3;383(23):2283-2285. doi: 10.1056/NEJMe2031294.
    Nat Rev Clin Oncol. 2021 Feb;18(2):63. doi: 10.1038/s41571-020-00464-y.
    N Engl J Med. 2021 Mar 11;384(10):971-972. doi: 10.1056/NEJMc2036233.
    N Engl J Med. 2021 Mar 11;384(10):972. doi: 10.1056/NEJMc2036233.
    Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1255-1262. doi: 
10.1016/j.ijrobp.2021.03.016.

BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in 
microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) 
tumors after previous therapy. The efficacy of PD-1 blockade as compared with 
chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic 
colorectal cancer is unknown.
METHODS: In this phase 3, open-label trial, 307 patients with metastatic 
MSI-H-dMMR colorectal cancer who had not previously received treatment were 
randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg 
every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without 
bevacizumab or cetuximab) every 2 weeks. Patients receiving chemotherapy could 
cross over to pembrolizumab therapy after disease progression. The two primary 
end points were progression-free survival and overall survival.
RESULTS: At the second interim analysis, after a median follow-up (from 
randomization to data cutoff) of 32.4 months (range, 24.0 to 48.3), 
pembrolizumab was superior to chemotherapy with respect to progression-free 
survival (median, 16.5 vs. 8.2 months; hazard ratio, 0.60; 95% confidence 
interval [CI], 0.45 to 0.80; P = 0.0002). The estimated restricted mean survival 
after 24 months of follow-up was 13.7 months (range, 12.0 to 15.4) as compared 
with 10.8 months (range, 9.4 to 12.2). As of the data cutoff date, 56 patients 
in the pembrolizumab group and 69 in the chemotherapy group had died. Data on 
overall survival were still evolving (66% of required events had occurred) and 
remain blinded until the final analysis. An overall response (complete or 
partial response), as evaluated with Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.1, was observed in 43.8% of the patients in the 
pembrolizumab group and 33.1% in the chemotherapy group. Among patients with an 
overall response, 83% in the pembrolizumab group, as compared with 35% of 
patients in the chemotherapy group, had ongoing responses at 24 months. 
Treatment-related adverse events of grade 3 or higher occurred in 22% of the 
patients in the pembrolizumab group, as compared with 66% (including one patient 
who died) in the chemotherapy group.
CONCLUSIONS: Pembrolizumab led to significantly longer progression-free survival 
than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic 
colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck 
Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov 
number, NCT02563002.).

Copyright © 2020 Massachusetts Medical Society.

DOI: 10.1056/NEJMoa2017699
PMID: 33264544 [Indexed for MEDLINE]